Tocilizumab for the Prevention of Graft Versus Host Disease After Cord Blood Transplantation

Inclusion Criteria: I. Acute myelogenous leukemia (AML) * Complete first remission (CR1) at high risk for relapse such as any of the following: * Known prior diagnosis of myelodysplasia (MDS) or myeloproliferative disorder * Therapy-related AML * White cell count at presentation \> 100,000 * Presence of extramedullary leukemia at diagnosis * Any unfavorable subtype by FAB or WHO classification * High-risk cytogenetics (e.g. those associated with MDS, abnormalities of 5, 7, 8, complex karyotype) or high risk molecular abnormalities * Requirement for 2 or more induction to achieve CR1 * Any patient with newly diagnosed AML with intermediate risk cytogenetics who elects allograft with curative intent over consolidation chemotherapy * Any patient unable to tolerate consolidation chemotherapy as would have been deemed appropriate by the treating physician * Other high risk features not defined above * Complete second remission (CR2) * Primary refractory or relapsed AML with less than 10% blasts before transplant. Persistent/relapsed AML with cytogenetic, flow cytometric, or molecular aberrations in \>/= 10% of cells are eligible II. Acute lymphoblastic leukemia (ALL) * Complete first remission (CR1) at high risk for relapse such as any of the following: * White cell count at presentation \> 30,000 for B-cell lineage and \> 100,00 for T-cell lineage * Presence of any high-risk cytogenetic abnormalities such as t(9;22), t(1;19), t(4;11) or other MLL rearrangements (11q23) or oth…